Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma
- PMID: 30710169
- DOI: 10.1007/s00428-018-02516-2
Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma
Abstract
The two most frequent types of endometrial cancer (EC) are endometrioid (EEC) and serous carcinomas (SC). Differential diagnosis between them is not always easy. A subset of endometrial cancers shows misleading microscopical features, which cause problems in differential diagnosis, and may be a good scenario for next-generation sequencing. Previous studies have assessed the usefulness of targeted sequencing with panels of generic cancer-associated genes in EC histological typing. Based on the analysis of TCGA (The Cancer Genome Atlas), EEC and SC have different mutational profiles. In this proof of principle study, we have performed targeted sequencing analysis with a customized panel, based on the TCGA mutational profile of EEC and SC, in a series of 24 tumors (16 EEC and 8 SC). Our panel comprised coding and non-coding sequences of the following genes: ABCC9, ARID1A, ARID5B, ATR, BCOR, CCND1, CDH19, CHD4, COL11A1, CSDE1, CSMD3, CTCF, CTNNB1, EP300, ERBB2, FBXW7, FGFR2, FOXA2, KLLN, KMT2B, KRAS, MAP3K4, MKI67, NRAS, PGAP3, PIK3CA, PIK3R1, PPP2R1A, PRPF18, PTEN, RPL22, SCARNA11, SIN3A, SMARCA4, SPOP, TAF1, TP53, TSPYL2, USP36, and WRAP53. Targeted sequencing validation by Sanger sequencing and immunohistochemistry was performed in a group of genes. POLE mutation status was assessed by Sanger sequencing. The most mutated genes were PTEN (93.7%), ARID1A (68.7%), PIK3CA (50%), and KMT2B (43.7%) for EEC, and TP53 (87.5%), PIK3CA (50%), and PPP2R1A (25%) for SC. Our panel allowed correct classification of all tumors in the two categories (EEC, SC). Coexistence of mutations in PTEN, ARID1A, and KMT2B was diagnostic of EEC. On the other hand, absence of PTEN, ARID1A, and KMT2B mutations in the presence of TP53 mutation was diagnostic of SC. This proof of concept study demonstrates the suitability of targeted sequencing with a customized endometrial cancer gene panel as an additional tool for confirming histological typing.
Keywords: Biomarker; Endometrial carcinoma; Endometrioid; Histological type; Serous; Targeted sequencing.
Similar articles
-
Use of mutation profiles to refine the classification of endometrial carcinomas.J Pathol. 2012 Sep;228(1):20-30. doi: 10.1002/path.4056. Epub 2012 Jul 18. J Pathol. 2012. PMID: 22653804 Free PMC article.
-
Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas.Virchows Arch. 2015 Apr;466(4):415-22. doi: 10.1007/s00428-015-1728-5. Epub 2015 Feb 13. Virchows Arch. 2015. PMID: 25677978
-
The genetic landscape of endometrial clear cell carcinomas.J Pathol. 2017 Oct;243(2):230-241. doi: 10.1002/path.4947. Epub 2017 Sep 5. J Pathol. 2017. PMID: 28718916 Free PMC article.
-
Molecular Genetics of Endometrial Carcinoma.Annu Rev Pathol. 2019 Jan 24;14:339-367. doi: 10.1146/annurev-pathol-020117-043609. Epub 2018 Oct 17. Annu Rev Pathol. 2019. PMID: 30332563 Review.
-
The Role of Genetic Mutations in Mitochondrial-Driven Cancer Growth in Selected Tumors: Breast and Gynecological Malignancies.Life (Basel). 2023 Apr 12;13(4):996. doi: 10.3390/life13040996. Life (Basel). 2023. PMID: 37109525 Free PMC article. Review.
Cited by
-
The Emerging Role of Chromatin Remodeling Complexes in Ovarian Cancer.Int J Mol Sci. 2022 Nov 8;23(22):13670. doi: 10.3390/ijms232213670. Int J Mol Sci. 2022. PMID: 36430148 Free PMC article. Review.
-
Genomic alterations in gynecological malignancies: histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms.J Hum Genet. 2021 Sep;66(9):853-868. doi: 10.1038/s10038-021-00940-y. Epub 2021 Jun 7. J Hum Genet. 2021. PMID: 34092788 Review.
-
Identification of Potential Crucial Genes Associated With the Pathogenesis and Prognosis of Endometrial Cancer.Front Genet. 2019 Apr 26;10:373. doi: 10.3389/fgene.2019.00373. eCollection 2019. Front Genet. 2019. PMID: 31105744 Free PMC article.
-
The Role of FBXW7 in Gynecologic Malignancies.Cells. 2023 May 17;12(10):1415. doi: 10.3390/cells12101415. Cells. 2023. PMID: 37408248 Free PMC article. Review.
-
BUB1, BUB1B, CCNA2, and CDCA8, along with miR-524-5p, as clinically relevant biomarkers for the diagnosis and treatment of endometrial carcinoma.BMC Cancer. 2023 Oct 18;23(1):995. doi: 10.1186/s12885-023-11515-9. BMC Cancer. 2023. PMID: 37853361 Free PMC article.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous